Business
Akoustis Announces Pricing of Public Offering of $10.0 Million of Common Stock
Board Co-Chair, CEO, CPO, and Other Company Management and Employees Investing $1 Million Charlotte, N.C., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Akoustis
About this update from Aktis Oncology, Inc.
[{"type":"text","content":" Board Co-Chair, CEO, CPO, and Other Company Management and Employees Investing $1 Million Charlotte, N.C., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ: AKTS) (“Akoustis” or the “Company”), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, announced today that it has priced its underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $0.50 per share. Akoustis expects the gross proceeds from the offering to be approximately $10.0 million, before deducting the underwriting discount and other estimated offering expenses payable by Akoustis. Roth Capital Partners is acting as sole manager for the offering. Akoustis intends to use the net proceeds from the proposed offering to fund operations and the growth of its business, including for capital expenditures, working capital, research and development, the commercialization of its technology, potential strategic transactions and for other general corporate purposes. Akoustis has granted the underwriters in the offering a 30-day option to purchase up to 3,000,000 additional shares of common stock solely to cover over-allotments. Akoustis expects to close the offering, subject to market and other conditions, on or about January 29, 2024. A shelf registration statement on Form S-3 (File No. 333-262540) relating to the shares of common stock to be issued in the offering was previously filed with the Securities and Exchange Commission (the “SEC”) and is currently effective. A preliminary prospectus supplement and accompanying prospectus describing the terms of the offering have been filed with the SEC on January 24, 2024, and a final prospectus supplement and accompanying prospectus with respect to the offering will be filed with the SEC. Copies of the final prospectus supplement and the accompanying prospectus relating to the securities being offered may be obtained, when available, from Roth Capital Partners, LLC, 888 San Clemente, Suite 400, Newport Beach, CA 92660, by telephone at (800) 678-9147 or by email at [email protected]. Electronic copies of the final prospectus supplement and accompanying prospectus will also be available on the SEC's website at http://www.sec.gov. This press release does not constitute an offer to sell...